137 related articles for article (PubMed ID: 20043719)
1. Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.
Thaker NG; Zhang F; McDonald PR; Shun TY; Lazo JS; Pollack IF
Neurosurg Focus; 2010 Jan; 28(1):E4. PubMed ID: 20043719
[TBL] [Abstract][Full Text] [Related]
2. Functional genomics to explore cancer cell vulnerabilities.
Kahle KT; Kozono D; Ng K; Hsieh G; Zinn PO; Nitta M; Chen CC
Neurosurg Focus; 2010 Jan; 28(1):E5. PubMed ID: 20043720
[TBL] [Abstract][Full Text] [Related]
3. Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets.
Thaker NG; McDonald PR; Zhang F; Kitchens CA; Shun TY; Pollack IF; Lazo JS
J Neurosci Methods; 2010 Jan; 185(2):204-12. PubMed ID: 19782703
[TBL] [Abstract][Full Text] [Related]
4. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine.
Zhao Z; Liu Y; He H; Chen X; Chen J; Lu YC
Brain Res Bull; 2011 Oct; 86(3-4):189-94. PubMed ID: 21807073
[TBL] [Abstract][Full Text] [Related]
5. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
[TBL] [Abstract][Full Text] [Related]
6. [Dysregulation of Long Non-coding RNAs in Glioblastoma Multiforme and Their Study Through Use of Modern Molecular-Genetic Approaches].
Večeřa M; Šána J; Bútová R; Reguli Š; Hermanová M; Křen L; Lipina R; Smrčka M; Slabý O
Klin Onkol; 2018; 31(Supplementum1):168-170. PubMed ID: 29808696
[TBL] [Abstract][Full Text] [Related]
7. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method.
Kunkle B; Yoo C; Roy D
Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis of micro-RNA, gene expression, and survival of glioblastoma multiforme.
Huang YT; Hsu T; Kelsey KT; Lin CL
Genet Epidemiol; 2015 Feb; 39(2):134-43. PubMed ID: 25537983
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.
Kim YW; Liu TJ; Koul D; Tiao N; Feroze AH; Wang J; Powis G; Yung WK
Neuro Oncol; 2011 Apr; 13(4):367-75. PubMed ID: 21430111
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death.
Colen RR; Wang J; Singh SK; Gutman DA; Zinn PO
Radiology; 2015 Apr; 275(1):215-27. PubMed ID: 25490189
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeting of glioblastoma: Drug discovery and therapies.
Bai RY; Staedtke V; Riggins GJ
Trends Mol Med; 2011 Jun; 17(6):301-312. PubMed ID: 21411370
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
13. MiR-224 expression increases radiation sensitivity of glioblastoma cells.
Upraity S; Kazi S; Padul V; Shirsat NV
Biochem Biophys Res Commun; 2014 May; 448(2):225-30. PubMed ID: 24785373
[TBL] [Abstract][Full Text] [Related]
14. NFATc1 activation promotes the invasion of U251 human glioblastoma multiforme cells through COX-2.
Wang L; Wang Z; Li J; Zhang W; Ren F; Yue W
Int J Mol Med; 2015 May; 35(5):1333-40. PubMed ID: 25738651
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.
Xu D; Zhou D; Bum-Erdene K; Bailey BJ; Sishtla K; Liu S; Wan J; Aryal UK; Lee JA; Wells CD; Fishel ML; Corson TW; Pollok KE; Meroueh SO
ACS Chem Biol; 2020 Jun; 15(6):1424-1444. PubMed ID: 32243127
[TBL] [Abstract][Full Text] [Related]
16. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
17. Applications of emerging molecular technologies in glioblastoma multiforme.
Kumar HR; Zhong X; Sandoval JA; Hickey RJ; Malkas LH
Expert Rev Neurother; 2008 Oct; 8(10):1497-506. PubMed ID: 18928343
[TBL] [Abstract][Full Text] [Related]
18. Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
[TBL] [Abstract][Full Text] [Related]
19. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data.
Cheng HW; Liang YH; Kuo YL; Chuu CP; Lin CY; Lee MH; Wu AT; Yeh CT; Chen EI; Whang-Peng J; Su CL; Huang CY
Cell Death Dis; 2015 May; 6(5):e1753. PubMed ID: 25950483
[TBL] [Abstract][Full Text] [Related]
20. Identification of survival genes in human glioblastoma cells by small interfering RNA screening.
Thaker NG; Zhang F; McDonald PR; Shun TY; Lewen MD; Pollack IF; Lazo JS
Mol Pharmacol; 2009 Dec; 76(6):1246-55. PubMed ID: 19783622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
